Surzebiclimab, the experimental therapeutic agent, is a significant step in treating self-reactive conditions. It targets the IL-17 receptor A, a molecule contributing to immune responses and various self-reactive illnesses, like psoriasis. Initial research suggest some positive reduction in indi

Osocimab, formerly known as BAY 1213790, represents a novel monoclonal antibody currently in clinical development for the therapy of several hematologic cancers. This agent specifically targets CD38, a surface receptor abundant on abnormal cells in diseases like multiple myeloma and acute myeloid